



COPY OF PAPERS
ORIGINALLY FILED

PATENT
Attorney Docket No. 203884

TECH CENTER 1600/2900

MAY 10 2002

1618
entg/15/02
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ullrich et al.

Application No. 09/600,826

Filed: September 7, 2000

Art Unit: 1614

Examiner: J. F. Murphy

FEB 19 2002

TECH CENTER 1600/2900

For: USE OF INHIBITORS FOR THE
TREATMENT OF RTK-HYPERFUNCTION-
INDUCED DISORDERS, PARTICULARLY
CANCER

SUPPLEMENTAL PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

Replace the paragraph beginning at page 14, line 16, with:

B2
FGFR-4^{388Arg} and FGFR-4wt were amplified by the PCR reaction. For this, the following primers were used: sense-GCTCAGAGGGCGGGCGGGGGTGCCGGCCG [SEQ ID NO: 3]; anti-sense CCGCTCGAGTGCCTGCACAGCCTTGAGCCTTGC [SEQ ID NO: 4]. For the PCR reaction, the following were used: 1.5 U/25 μ l Expand-Polymerase (Boehringer, Mannheim) and reaction buffer according to the manufacturer's instructions: 200 μ M dNTP's; 0.01% v/v Triton X100; 10% v/v DMSO, and 0.2 pmol each of sense and α -sense primer. The following reaction steps were performed: 35 cycles, 94°C 1 min, 64°C 1 min, 72°C 2.5 min. MDA-MB-453 cDNA was used for the cloning of FGFR-4^{388Arg}, and K562 cDNA for the cloning of FGFR-4wt. The PCR products were cloned in the pcDNA3 vector (Invitrogen). In this way, both a FGFR-4 with the G388R and also a wild type FGFR-4 could be obtained for further tests.